

On page 52, line 22, after 3'), insert -- (SEQ ID NO:46)--.

On page 52, line 24, after 3'), insert --(SEQ ID NO:47)--.

On page 68, line 1 please insert the following:

--ABSTRACT

92 The present invention relates to genetically engineered recombinant Respiratory Syncytial Viruses and viral vectors which contain heterologous genes for use as vaccines. In accordance with the present invention, the recombinant RSV viral vectors and viruses are engineered to contain heterologous genes, including genes of other viruses, pathogens, cellular genes, tumor antigens, or to encode combinations of genes from different strains of RSV.--

IN THE SEQUENCE LISTING

Please amend the sequence listing by entering the replacement sequence listing enclosed herewith pursuant to 37 C.F.R. § 1.825.

IN THE CLAIMS:

Please amend claims 2, 13 and 18 to read as follows:

93 2. (Amended) An isolated infectious Respiratory Syncytial Virus (RSV) particle containing an RSV RNA comprising a binding site specific for an RNA-directed RNA polymerase operatively linked to an RSV RNA comprising sequences encoding antigenic polypeptides of both RSV-A and RSV-B.

94 13. (Amended) A vaccine comprising a chimeric Respiratory Syncytial Virus (RSV) the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of an RSV and a pharmaceutically acceptable carrier.

95 18. (Amended) The vaccine of Claim 13 in which the mRNA coding sequence encodes G and F genes of both Respiratory Syncytial Virus A and Respiratory Syncytial Virus B.
